Dave Levitan

Vemurafenib offered numerical improvement in disease-free survival in patients with resected melanoma, but the results did not reach statistical significance.

Incorporating MRI-based parameters into a risk model could cut down on the number of unnecessary biopsies performed in patients with suspected prostate cancer.

Circulating tumor DNA can help differentiate pseudoprogression from true progression in patients with melanoma who are treated with PD-1 inhibitors.

The significant tumor shrinkage and immunologic changes observed support a complementary role of SBRT and PD-1 immunotherapy, investigators concluded.

Early-phase data on larotrectinib validate TRK fusions as therapeutic targets and show they lead to tumor-agnostic sensitivity to this agent.

A retrospective review found that obesity is associated with improved progression-free and overall survival in certain patients with metastatic melanoma.

The observed narrowing of racial disparities in prostate cancer outcome since the advent of PSA screening is not as large as previously believed.

Patients with ER-negative, but not ER-positive, isolated locoregional recurrence after unilateral breast cancer derive significant benefit from chemotherapy.

A phase II trial found that the immune checkpoint inhibitor durvalumab has promising clinical activity and is well tolerated both as monotherapy and in combination with tremelimumab in patients with heavily pretreated recurrent or metastatic head and neck cancer, whose tumors are PD-L1 low or negative.

An early phase trial found that it is feasible to combine nivolumab immunotherapy with radiation therapy and chemotherapy in patients with newly diagnosed local-regionally advanced head and neck cancers.

Cabozantinib showed significant antitumor activity in the treatment of differentiated thyroid cancer that progressed following surgery and radioactive iodine therapy, according to a new phase II study.

The addition of metronomic chemotherapy to dual HER2 blockade improved outcomes in older and frail patients with HER2-positive metastatic breast cancer.

Patients with human papillomavirus–associated head and neck cancers who respond well to induction therapy can receive substantially lower doses of radiation and still achieve good safety and efficacy outcomes, according to a new phase II trial.

Maintenance therapy with pazopanib significantly prolonged progression-free survival in patients with extensive-disease small-cell lung cancer, but with toxicity.

Several markers of bone formation and resorption were found to be predictive of bone-specific recurrence in patients with early breast cancer.

Long-term follow-up showed that atezolizumab remained well tolerated over more than 3 years, with durable clinical benefit in metastatic urothelial carcinoma.

Lifastuzumab vedotin offered a modest improvement in progression-free survival over standard care in patients with platinum-resistant ovarian cancer.

Nivolumab offers extended overall survival benefit vs docetaxel in patients with advanced non–small-cell lung cancer, according to an analysis with 3 years of follow-up.

A meta-analysis incorporating tens of thousands of individuals found no association between the use of antidepressants and the risk of epithelial ovarian cancer.

A trastuzumab biosimilar known as SB3 showed equivalent efficacy and safety to trastuzumab itself in a phase III trial of women with early HER2-positive breast cancer in the neoadjuvant setting.

Adjuvant radiotherapy after prostatectomy resulted in lower rates of biochemical recurrence, distant metastases, and death compared with surveillance followed by early-salvage radiotherapy in patients with high-risk prostate cancer, according to a new study.

The PAM50 risk of recurrence score can improve the prediction of recurrence at 10 years in postmenopausal patients with HR-positive early breast cancer.

Long-term follow-up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival over ADT alone in metastatic hormone-sensitive prostate cancer patients with high-volume disease.

Adding palbociclib to letrozole offers similar health-related quality of life and better pain scores in postmenopausal women with estrogen receptor–positive/HER2-negative metastatic breast cancer, compared to letrozole alone, according to an analysis of the PALOMA-2 trial.

A combined approach targeting ER, HER2, and RB1 yielded promising results in terms of Ki-67 expression in women with HER2-positive, ER-positive breast cancer.

No difference was found in pathologic complete response rates between neoadjuvant paclitaxel and nab-paclitaxel in women with ERBB2/HER2-negative breast cancer.

Adding bevacizumab maintenance therapy failed to improve outcomes compared with no treatment when administered during chemotherapy-free intervals to patients with metastatic colorectal cancer after induction chemotherapy.

A comparison of margin classification systems revealed some differences in their ability to determine local recurrence risk for soft-tissue sarcoma.

The time to testosterone rebound was associated with differences in prostate cancer–specific and cardiovascular mortality among men who underwent RT and ADT.

ASCO recently released a clinical practice guideline on the treatment of malignant pleural mesothelioma, including recommendations on diagnosis, staging, and treatment with chemotherapy, surgical cytoreduction, and radiation therapy.